atai

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price on Jan. 11 was $1.72, more than 90% below its IPO price from...

In an interview with Complex to promote his clothing brand MSFTSrep, Jaden Smith talked about his experience with psychedelics and said he is looking to be a “psychedelics world leader.” MSFTrep's latest collection is an ode to the psychedelic counterculture of the sixties:...